Deutsche Bank’s Cartesian Therapeutics RNAC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $49.9K | Buy |
8,116
+4
| +0% | +$28 | ﹤0.01% | 3478 |
|
|
2025
Q4 | $58.5K | Buy |
8,112
+688
| +9% | +$5.56K | ﹤0.01% | 3426 |
|
|
2025
Q3 | $75.9K | Hold |
7,424
| – | – | ﹤0.01% | 3379 |
|
|
2025
Q2 | $77.1K | Hold |
7,424
| – | – | ﹤0.01% | 3344 |
|
|
2025
Q1 | $97.8K | Buy |
7,424
+3,786
| +104% | +$67.6K | ﹤0.01% | 3202 |
|
|
2024
Q4 | $65.2K | Hold |
3,638
| – | – | ﹤0.01% | 3379 |
|
|
2024
Q3 | $58.6K | Hold |
3,638
| – | – | ﹤0.01% | 3337 |
|
|
2024
Q2 | $98.3K | Buy |
3,638
+1,444
| +66% | +$34.5K | ﹤0.01% | 3112 |
|
|
2024
Q1 | $42.8K | Hold |
2,194
| – | – | ﹤0.01% | 3425 |
|
|
2023
Q4 | $45.4K | Hold |
2,194
| – | – | ﹤0.01% | 3431 |
|
|
2023
Q3 | $69.8K | Buy |
+2,194
| New | +$73.3K | ﹤0.01% | 3320 |
|
|
2022
Q4 | – | Sell |
-18,576
| Closed | -$914K | – | 4041 |
|
|
2022
Q3 | $914K | Buy |
18,576
+85
| +0.5% | +$4.67K | ﹤0.01% | 2024 |
|
|
2022
Q2 | $727K | Sell |
18,491
-7,129
| -28% | -$211K | ﹤0.01% | 2373 |
|
|
2022
Q1 | $946K | Sell |
25,620
-198
| -0.8% | -$12.4K | ﹤0.01% | 2384 |
|
|
2021
Q4 | $2.52M | Buy |
25,818
+5,827
| +29% | +$627K | ﹤0.01% | 1839 |
|
|
2021
Q3 | $2.5M | Sell |
19,991
-2,212
| -10% | -$267K | ﹤0.01% | 1929 |
|
|
2021
Q2 | $2.79M | Sell |
22,203
-3,335
| -13% | -$397K | ﹤0.01% | 1929 |
|
|
2021
Q1 | $3.47M | Buy |
25,538
+1,386
| +6% | +$172K | ﹤0.01% | 1791 |
|
|
2020
Q4 | $2.2M | Buy |
24,152
+22,944
| +1,899% | +$1.99M | ﹤0.01% | 1892 |
|
|
2020
Q3 | $90K | Buy |
1,208
+167
| +16% | +$12.8K | ﹤0.01% | 3601 |
|
|
2020
Q2 | $89K | Buy |
+1,041
| New | +$94.4K | ﹤0.01% | 3498 |
|
|
2020
Q1 | – | Sell |
-215
| Closed | -$15K | – | 4744 |
|
|
2019
Q4 | $15K | Sell |
215
-388
| -64% | -$18.7K | ﹤0.01% | 4387 |
|
|
2019
Q3 | $31K | Buy |
603
+309
| +105% | +$16.4K | ﹤0.01% | 4153 |
|
|
2019
Q2 | $15K | Sell |
294
-1,119
| -79% | -$76.3K | ﹤0.01% | 4879 |
|
|
2019
Q1 | $100K | Sell |
1,413
-2,824
| -67% | -$179K | ﹤0.01% | 4312 |
|
|
2018
Q4 | $337K | Buy |
4,237
+2,874
| +211% | +$656K | ﹤0.01% | 3576 |
|
|
2018
Q3 | $636K | Buy |
1,363
+196
| +17% | +$78.7K | ﹤0.01% | 3633 |
|
|
2018
Q2 | $463K | Buy |
1,167
+549
| +89% | +$195K | ﹤0.01% | 3886 |
|
|
2018
Q1 | $188K | Sell |
618
-441
| -42% | -$126K | ﹤0.01% | 4225 |
|
|
2017
Q4 | $311K | Sell |
1,059
-459
| -30% | -$201K | ﹤0.01% | 3826 |
|
|
2017
Q3 | $830K | Buy |
1,518
+1,072
| +240% | +$570K | ﹤0.01% | 3144 |
|
|
2017
Q2 | $264K | Buy |
446
+404
| +962% | +$178K | ﹤0.01% | 3784 |
|
|
2017
Q1 | $17K | Sell |
42
-66
| -61% | -$27.8K | ﹤0.01% | 4545 |
|
|
2016
Q4 | $54K | Buy |
+108
| New | +$63.1K | ﹤0.01% | 4333 |
|
Other funds holding RNAC
VCM
6CM
EAM
Deutsche Bank's RNAC Position: Q1 2026 in Review
Deutsche Bank increased its Cartesian Therapeutics (RNAC) stake by 0.05% in Q1 2026, buying an estimated $28 and bringing the position to 8,116 shares worth $49.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3478.
Deutsche Bank first reported a position in RNAC in Q4 2016 and has held it in 34 quarters since. The position peaked at $3.47M in Q1 2021. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.
- Deutsche Bank held 8,116 shares of Cartesian Therapeutics worth $49.9K as of Q1 2026.
- Deutsche Bank bought 4 Cartesian Therapeutics shares in Q1 2026, an estimated $28.
- Cartesian Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #3478 holding.
- Deutsche Bank first reported a position in Cartesian Therapeutics in Q4 2016 and has held it in 34 quarters since.
- Deutsche Bank's Cartesian Therapeutics position peaked at $3.47M in Q1 2021.
- 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.
Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.